In June 2025, the company VERTEX made its first delivery of medicines and cosmetics to the Lao People's Democratic Republic. The country became the first in the Southeast Asian and Asia-Pacific export markets, the company’s press service reported.
Previously, the company's products were primarily available in Commonwealth of Independent States (CIS) countries and neighboring friendly states. It took about a year to implement the project for deliveries to Laos, during which the Russian manufacturer coordinated logistics and financial operations.
“Laos is a small market for our company, but it will help us assess the potential of similar projects, including from the perspective of refining logistics mechanisms,” said Georgy Pobelyansky, General Director of pharmaceutical company VERTEX. He emphasized that the company is building its drug portfolio based on global demand for treatment of the most common diseases. Cosmetic products are developed with current trends in mind. “Taking into account the demand for different product categories, we plan to further promote them in other markets,” he concluded.
The company sent both original and generic drugs to Laos. Among them are:
- dermatological preparations "Tetraderm®" and "Rederm®";
- nasal spray with framycetin for adults and children;
- medicine for treating bronchial asthma and respiratory system diseases with the active ingredient montelukast;
- a drug for musculoskeletal problems containing chondroitin.
VERTEX also delivered cosmetic brands for skin and hair care: "La-Cri" and LE SANTI, as well as anti-edema and refreshing foot care products from the "Normaven" line.
The products were shipped to Laos in Russian packaging. Consumer information stickers will be added at the destination. The goods are intended for the pharmacy segment. Based on sales results, the company will decide whether to expand the product range and increase sales volumes. Deliveries of Russian-made medicines are carried out in coordination with the Ministry of Health of Laos, without registration under national rules.
Source: PHARMEDPROM
